Wyeth-Ayerst Norplant labeling to include patient acknowledgement form.
WYETH-AYERST NORPLANT PATIENT ACKNOWLEDGEMENT FORM IN LABELING will allow "patients to acknowledge receipt of information" about the implantable contraceptive levonorgestrel. The form also provides "the opportunity for thorough discussion regarding Norplant prior to insertion," FDA said in a "Talk Paper" released Aug. 17. Use of the acknowledgement form by physicians is voluntary, Wyeth-Ayerst said. Patients also are not required to sign. The company noted that the form is not intended to supplant other educational materials about Norplant.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth